List of adverse effects of nilotinib

This is a list of adverse effects of the anti-cancer drug nilotinib, sorted by frequency of occurrence. ^{[1] [2] [3] [4] [5] [6]}

Very common

Very common (>10% incidence) adverse effects include:

• Headache
• Nausea
• Hypophosphataemia
• Hyperbilirubinaemia
• Alanine aminotransferase (ALT) increased
• Aspartate aminotransferase increased
• Lipase increased
• Rash
• Itchiness
• Hair loss
• Dry skin
• Muscle aches
• Fatigue

Common

Common (1–10% incidence) adverse effects include:

• Constipation
• Diarrhoea
• Vomiting
• Upper abdominal pain
• Indigestion
• Joint pain
• Muscle spasms
• Pain in extremities
• Asthenia
• Peripheral oedema
• Folliculitis
• Upper respiratory tract infection (including pharyngitis, nasopharyngitis, rhinitis)
• Skin papilloma
• Eosinophilia
• Lymphopenia
• Insomnia
• Anxiety
• Depression
• Diabetes mellitus
• Hypercholesterolaemia
• Hyperlipidaemia
• Hypertriglyceridaemia
• Hyperglycaemia
• Loss of appetite
• Dizziness
• Hypoaesthesia
• Peripheral neuropathy
• Eye pruritus
• Conjunctivitis
• Dry eye (including xerophthalmia)
• Vertigo
• Flushing
• Hypertension
• Angina pectoris
• Arrhythmia (including atrioventricular block, tachycardia, atrial fibrillation, ventricular extrasystoles, bradycardia)
• QT interval prolonged
• Palpitations
• Cough
• Dyspnoea
• Abdominal distension
• Abdominal discomfort
• Taste changes
• Flatulence
• Abnormal liver function
• Bone pain
• Back pain
• Erythema
• Hyperhidrosis
• Contusion
• Acne
• Dermatitis (including allergic, exfoliative and acneiform)
• Night sweats
• Fever without an infectious cause
• Chest pain (including non-cardiac chest pain)
• Chest discomfort
• Decreased haemoglobin
• Increased blood amylase
• Increased blood alkaline phosphatase
• Gamma-glutamyltransferase increased
• Weight increased
• Increased blood insulin
• Increased lipoprotein (including very low density and high density)

Uncommon

Uncommon (0.1–1% incidence) adverse effects include:

• Arteriosclerosis
• Bone marrow suppression
• Both increases and decreases of potassium levels
• Body temperature change sensation (both hot and cold)
• Chills
• Cognitive deficits ^[7]
• Conjunctival bleeding and redness
• Cyanosis
• Dental sensitivity to pain
• Bleeding into the lungs ^[8]
• Increased blood cholesterol and lipid levels
• Dystonia ^[7]
• Erectile dysfunction
• Eyelid swelling
• Flank pain
• Gastritis
• Gout
• Decreased calcium levels
• Jaundice
• Malaise
• Migraine
• Muscle pain and weakness
• Pancreatitis
• Paraesthesia
• Peripheral arterial occlusive disease
• Photopsia
• Pleural effusion
• Skin eruptions
• Skin pain
• Decreased globulins

References

1. "Complete Nilotinib information from Drugs.com". Drugs.com. Retrieved 25 January 2014.
2. "Tasigna: EPAR - Product Information" (PDF). European Medicines Agency. Novartis Europharm Ltd. 18 October 2013. Retrieved 25 January 2014.
3. "Tasigna 150mg Hard Capsules - Summary of Product Characteristics (SPC)". electronic Medicines Compendium. Novartis Pharmaceuticals UK Ltd. 9 September 2013. Retrieved 25 January 2014.
4. "TASIGNA® nilotinib" (PDF). TGA eBusiness Services. 21 October 2013. Retrieved 25 January 2014.
5. "Tasigna (nilotinib) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 25 January 2014.
6. Rossi, S, ed. (2013). Australian Medicines Handbook (2013 ed.). Adelaide: The Australian Medicines Handbook Unit Trust. ISBN   978-0-9805790-9-3.
7. Chan, J; Shah, P; Moguel-Cobos, G (2019). "Nilotinib-Induced Dystonia and Cognitive Deficits in a Neurologically Normal Patient with Chronic Myeloid Leukemia". Case Reports in Neurological Medicine. 2019 3679319. doi: 10.1155/2019/3679319 . PMC   6875312 . PMID   31781436.
8. Donatelli, C., D. Chongnarungsin, and R. Ashton. (Oct 2014). "Acute respiratory failure from nilotinib-associated diffuse alveolar hemorrhage". Leuk Lymphoma. 55 (10): 2408–9. doi:10.3109/10428194.2014.887714. PMID   24467220. S2CID   43118790.